| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0007 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.49 | 0.0007 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0007 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.0008 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | Zebularine | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.001 |
| mRNA | CGP-60474 | GDSC1000 | pan-cancer | AAC | 0.16 | 0.001 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | 0.16 | 0.001 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.14 | 0.001 |